|
1
|
Peng M, Watanabe S, Chan KW, He Q, Zhao Y,
Zhang Z, Lai X, Luo D, Vasudevan SG and Li G: Luteolin restricts
dengue virus replication through inhibition of the proprotein
convertase furin. Antiviral Res. 143:176–185. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Peng M, Swarbrick CMD, Chan KW, Luo D,
Zhang W, Lai X, Li G and Vasudevan SG: Luteolin escape mutants of
dengue virus map to prM and NS2B and reveal viral plasticity during
maturation. Antiviral Res. 154:87–96. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang H, Tan X, Yang D, Lu J, Liu B,
Baiyun R and Zhang Z: Dietary luteolin attenuates chronic liver
injury induced by mercuric chloride via the Nrf2/NF-κB/P53
signaling pathway in rats. Oncotarget. 8:40982–40993.
2017.PubMed/NCBI
|
|
4
|
Guo YF, Xu NN, Sun W, Zhao Y, Li CY and
Guo MY: Luteolin reduces inflammation in Staphylococcus
aureus-induced mastitis by inhibiting NF-κB activation and MMPs
expression. Oncotarget. 8:28481–28493. 2017.PubMed/NCBI
|
|
5
|
Zang Y, Igarashi K and Li Y: Anti-diabetic
effects of luteolin and luteolin-7-O-glucoside on
KK-Ay mice. Biosci Biotechnol Biochem.
80:1580–1586. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou Y, Ding BZ, Lin YP and Wang HB:
MiR-34a, as a suppressor, enhance the susceptibility of gastric
cancer cell to luteolin by directly targeting HK1. Gene. 644:56–65.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Byun EB, Song HY, Mushtaq S, Kim HM, Kang
JA, Yang MS, Sung NY, Jang BS and Byun EH: Gamma-irradiated
luteolin inhibits 3-isobutyl-1-methylxanthine-induced melanogenesis
through the regulation of CREB/MITF, PI3K/Akt, and ERK pathways in
B16BL6 melanoma cells. J Med Food. 20:812–819. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen P, Zhang JY, Sha BB, Ma YE, Hu T, Ma
YC, Sun H, Shi JX, Dong ZM and Li P: Luteolin inhibits cell
proliferation and induces cell apoptosis via down-regulation of
mitochondrial membrane potential in esophageal carcinoma cells EC1
and KYSE450. Oncotarget. 8:27471–27480. 2017.PubMed/NCBI
|
|
9
|
Wang Q, Wang H, Jia Y, Pan H and Ding H:
Luteolin induces apoptosis by ROS/ER stress and mitochondrial
dysfunction in gliomablastoma. Cancer Chemother Pharmacol.
79:1031–1041. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cao Z, Zhang H, Cai X, Fang W, Chai D, Wen
Y, Chen H, Chu F and Zhang Y: Luteolin promotes cell apoptosis by
inducing autophagy in hepatocellular carcinoma. Cell Physiol
Biochem. 43:1803–1812. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lim W, Yang C, Bazer FW and Song G:
Luteolin inhibits proliferation and induces apoptosis of human
placental choriocarcinoma cells by blocking the PI3K/AKT pathway
and regulating sterol regulatory element binding protein activity.
Biol Reprod. 95:822016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shen XF, Teng Y, Sha KH, Wang XY, Yang XL,
Guo XJ, Ren LB, Wang XY, Li J and Huang N: Dietary flavonoid
luteolin attenuates uropathogenic Escherichia. Coli invasion of the
urinary bladder. Biofactors. 42:674–685. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Krifa M, Leloup L, Ghedira K, Mousli M and
Chekir-Ghedira L: Luteolin induces apoptosis in BE colorectal
cancer cells by downregulating calpain, UHRF1, and DNMT1
expressions. Nutr Cancer. 66:1220–1227. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xavier CP, Lima CF, Preto A, Seruca R,
Fernandes-Ferreira M and Pereira-Wilson C: Luteolin, quercetin and
ursolic acid are potent inhibitors of proliferation and inducers of
apoptosis in both KRAS and BRAF mutated human colorectal cancer
cells. Cancer Lett. 281:162–170. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pandurangan AK, Dharmalingam P, Sadagopan
SK, Ramar M, Munusamy A and Ganapasam S: Luteolin induces growth
arrest in colon cancer cells through involvement of
Wnt/β-catenin/GSK-3β signaling. J Environ Pathol Toxicol Oncol.
32:131–139. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu Y, Lang T, Jin B, Chen F, Zhang Y,
Beuerman RW, Zhou L and Zhang Z: Luteolin inhibits colorectal
cancer cell epithelial-to-mesenchymal transition by suppressing
CREB1 expression revealed by comparative proteomics study. J
Proteomics. 161:1–10. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Manju V and Nalini N: Protective role of
luteolin in 1,2-dimethylhydrazine induced experimental colon
carcinogenesis. Cell Biochem Funct. 25:189–194. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ashokkumar P and Sudhandiran G: Protective
role of luteolin on the status of lipid peroxidation and
antioxidant defense against azoxymethane-induced experimental colon
carcinogenesis. Biomed Pharmacother. 62:590–597. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chian S, Li YY, Wang XJ and Tang XW:
Luteolin sensitizes two oxaliplatin-resistant colorectal cancer
cell lines to chemotherapeutic drugs via inhibition of the Nrf2
pathway. Asian Pac J Cancer Prev. 15:2911–2916. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qu Q, Qu J, Guo Y, Zhou BT and Zhou HH:
Luteolin potentiates the sensitivity of colorectal cancer cell
lines to oxaliplatin through the PPARγ/OCTN2 pathway. Anticancer
Drugs. 25:1016–1027. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lin S and Gregory RI: MicroRNA biogenesis
pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bracken CP, Scott HS and Goodall GJ: A
network-biology perspective of microRNA function and dysfunction in
cancer. Nat Rev Genet. 17:719–732. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Eichmuller SB, Osen W, Mandelboim O and
Seliger B: Immune modulatory microRNAs involved in tumor attack and
tumor immune escape. J Natl Cancer Inst. 109:2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Han K, Meng W, Zhang JJ, Zhou Y, Wang YL,
Su Y, Lin SC, Gan ZH, Sun YN and Min DL: Luteolin inhibited
proliferation and induced apoptosis of prostate cancer cells
through miR-301. Onco Targets Ther. 9:3085–3094. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jiang ZQ, Li MH, Qin YM, Jiang HY, Zhang X
and Wu MH: Luteolin inhibits tumorigenesis and induces apoptosis of
non-small cell lung cancer cells via regulation of microRNA-34a-5p.
Int J Mol Sci. 19:E4472018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang YX, Chen YR, Liu SS, Ye YP, Jiao HL,
Wang SY, Xiao ZY, Wei WT, Qiu JF, Liang L, et al: MiR-384 inhibits
human colorectal cancer metastasis by targeting KRAS and CDC42.
Oncotarget. 7:84826–84838. 2016.PubMed/NCBI
|
|
29
|
Kang KA, Piao MJ, Ryu YS, Hyun YJ, Park
JE, Shilnikova K, Zhen AX, Kang HK, Koh YS, Jeong YJ, et al:
Luteolin induces apoptotic cell death via antioxidant activity in
human colon cancer cells. Int J Oncol. 51:1169–1178. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Abdel Hadi L, Di Vito C, Marfia G,
Ferraretto A, Tringali C, Viani P and Riboni L: Sphingosine kinase
2 and ceramide transport as key targets of the natural flavonoid
luteolin to induce apoptosis in colon cancer cells. PLoS One.
10:e01433842015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Muramatsu T: Midkine and pleiotrophin: Two
related proteins involved in development, survival, inflammation
and tumorigenesis. J Biochem. 132:359–371. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yao J, Zhang LL, Huang XM, Li WY and Gao
SG: Pleiotrophin and N-syndecan promote perineural invasion and
tumor progression in an orthotopic mouse model of pancreatic
cancer. World J Gastroenterol. 23:3907–3914. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bai PS, Xia N, Sun H and Kong Y:
Pleiotrophin, a target of miR-384, promotes proliferation,
metastasis and lipogenesis in HBV-related hepatocellular carcinoma.
J Cell Mol Med. 21:3023–3043. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ma J, Kong Y, Nan H, Qu S, Fu X, Jiang L,
Wang W, Guo H, Zhao S, He J and Nan K: Pleiotrophin as a potential
biomarker in breast cancer patients. Clin Chim Acta. 466:6–12.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jee YH, Sadowski SM, Celi FS, Xi L,
Raffeld M, Sacks DB, Remaley AT, Wellstein A, Kebebew E and Baron
J: Increased pleiotrophin concentrations in papillary thyroid
cancer. PLoS One. 11:e01493832016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chang Y, Zuka M, Perez-Pinera P, Astudillo
A, Mortimer J, Berenson JR and Deuel TF: Secretion of pleiotrophin
stimulates breast cancer progression through remodeling of the
tumor microenvironment. Proc Natl Acad Sci USA. 104:10888–10893.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lampropoulou E, Logoviti I, Koutsioumpa M,
Hatziapostolou M, Polytarchou C, Skandalis SS, Hellman U, Fousteris
M, Nikolaropoulos S, Choleva E, et al: Cyclin-dependent kinase 5
mediates pleiotrophin-induced endothelial cell migration. Sci Rep.
8:58932018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shi Y, Ping YF, Zhou W, He ZC, Chen C,
Bian BS, Zhang L, Chen L, Lan X, Zhang XC, et al: Tumour-associated
macrophages secrete pleiotrophin to promote PTPRZ1 signalling in
glioblastoma stem cells for tumour growth. Nat Commun. 8:150802017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yamakawa T, Kurosawa N, Kadomatsu K,
Matsui T, Itoh K, Maeda N, Noda M and Muramatsu T: Levels of
expression of pleiotrophin and protein tyrosine phosphatase zeta
are decreased in human colorectal cancers. Cancer Lett. 135:91–96.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kong Y, Bai PS, Nan KJ, Sun H, Chen NZ and
Qi XG: Pleiotrophin is a potential colorectal cancer prognostic
factor that promotes VEGF expression and induces angiogenesis in
colorectal cancer. Int J Colorectal Dis. 27:287–298. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sun H, He L, Ma L, Lu T, Wei J, Xie K and
Wang X: LncRNA CRNDE promotes cell proliferation, invasion and
migration by competitively binding miR-384 in papillary thyroid
cancer. Oncotarget. 8:110552–110565. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang G, Pan J, Zhang L, Wei Y and Wang C:
Long non-coding RNA CRNDE sponges miR-384 to promote proliferation
and metastasis of pancreatic cancer cells through upregulating
IRS1. Cell Prolif. 50:2017. View Article : Google Scholar :
|
|
43
|
Fan N, Zhang J, Cheng C, Zhang X, Feng J
and Kong R: MicroRNA-384 represses the growth and invasion of
non-small-cell lung cancer by targeting astrocyte elevated
gene-1/Wnt signaling. Biomed Pharmacother. 95:1331–1337. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Song H, Rao Y, Zhang G and Kong X:
MicroRNA-384 inhibits the growth and invasion of renal cell
carcinoma cells by targeting astrocyte elevated gene 1. Oncol Res.
26:457–466. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zheng J, Liu X, Wang P, Xue Y, Ma J, Qu C
and Liu Y: CRNDE promotes malignant progression of glioma by
attenuating miR-384/PIWIL4/STAT3 axis. Mol Ther. 24:1199–1215.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chen Z, Yu C, Zhan L, Pan Y, Chen L and
Sun C: LncRNA CRNDE promotes hepatic carcinoma cell proliferation,
migration and invasion by suppressing miR-384. Am J Cancer Res.
6:2299–2309. 2016.PubMed/NCBI
|
